Axplora's Emissions Reduction Goals Validated by SBTi
Pharmaceutical manufacturer Axplora secures science-based emissions targets
Axplora, a global pharmaceutical manufacturing partner, has announced that its climate targets have been validated by the Science Based Targets initiative. The validation confirms that the company's emissions reduction goals align with international climate science. For businesses working in pharmaceutical supply chains, this development adds another data point to the growing expectation that suppliers will need to demonstrate credible carbon reduction plans.
The company has committed to cutting Scope 1 and 2 emissions by 42% and Scope 3 emissions by 25% by 2030. These targets form part of Axplora's ActNow 2030 climate plan, which the company describes as a framework for reducing emissions across its manufacturing network. Axplora specializes in small-molecule active pharmaceutical ingredients and antibody-drug conjugates, serving customers who are increasingly scrutinizing the environmental performance of their supply chains.
In practical terms, the validation provides independent confirmation that Axplora's targets meet established climate criteria. Consequently, pharmaceutical companies sourcing from Axplora can point to third-party verification when reporting on their own Scope 3 emissions. This matters because regulatory and commercial pressure on supply chain emissions continues to increase across the pharmaceutical sector.
Renewable electricity rollout across manufacturing sites
Axplora reports that 100% of its French manufacturing sites now run on renewable electricity. According to company materials, 61% of electricity across all global sites came from renewable sources in 2024. The company has stated it intends to extend renewable electricity use to all global operations by 2030.
The shift to renewable electricity directly reduces Scope 2 emissions, which arise from purchased energy. For manufacturers, this transition typically involves renegotiating energy contracts or investing in on-site generation. Axplora has not disclosed the commercial structure behind its renewable electricity procurement, but the move reflects a common approach among industrial businesses seeking to lower carbon intensity without redesigning core processes.
In addition to renewable electricity, Axplora has highlighted process-level decarbonization measures. These include flow chemistry, electrochemistry, and efficiency improvements designed to reduce energy consumption and waste. The company uses Process Mass Intensity as a metric to assess the environmental efficiency of manufacturing processes. This metric measures the total mass of materials used per kilogram of product, providing a quantifiable basis for comparing process designs.
Furthermore, Axplora says it applies a three-part approach to resource management: recycle, reuse, and revalorize. While the terminology is company-specific, the underlying principle involves minimizing waste by recovering materials and repurposing by-products where technically feasible. For pharmaceutical manufacturing, where regulatory constraints limit flexibility, this requires process engineering and compliance coordination.
What businesses need to know about SBTi validation
The Science Based Targets initiative is a partnership between CDP, the United Nations Global Compact, World Resources Institute, and World Wide Fund for Nature. It provides a framework for companies to set emissions reduction targets that align with climate science. Specifically, SBTi validates whether a company's targets are consistent with limiting global warming to 1.5°C above pre-industrial levels.
For businesses assessing suppliers, SBTi validation serves as a recognized benchmark. It indicates that a company has submitted its targets for independent review and that those targets meet defined criteria. However, validation does not guarantee that a company will meet its targets. It simply confirms that the targets are appropriately ambitious if achieved.
In procurement terms, this distinction matters. A validated target provides assurance that a supplier has committed to a credible trajectory. Nevertheless, businesses relying on supplier emissions data for their own reporting should track actual performance over time, not just target announcements. Reported progress in 2023 showed Axplora reduced absolute greenhouse gas emissions by 9% and emissions per million euros of sales by 6%, with renewable electricity consumption reaching 60% across the group.
Meanwhile, pharmaceutical companies face increasing scrutiny over Scope 3 emissions, which include purchased goods and services. Axplora's 25% reduction target for Scope 3 emissions is notable because it extends beyond the company's direct operations. Achieving this target will require engagement with Axplora's own suppliers, as well as changes to logistics, raw material sourcing, and waste management.
The commercial significance of SBTi validation has grown as more buyers incorporate carbon performance into supplier selection. In public procurement, frameworks such as PPN 06/21 in the UK require suppliers to publish carbon reduction plans. Although PPN 06/21 applies primarily to UK government contracts, similar expectations are emerging in private sector procurement across Europe. Therefore, suppliers with validated targets may find themselves better positioned in competitive tendering processes.
ESG framework covers climate, safety, and waste
Axplora's ESG program extends beyond climate action. The company organizes its sustainability roadmap around five pillars: health and safety, climate change, energy management, waste management, and diversity and inclusion. Each pillar addresses a different aspect of operational risk and regulatory compliance.
Health and safety remains a priority in pharmaceutical manufacturing due to the handling of active ingredients and chemical processes. Axplora has not disclosed specific safety performance metrics in its latest announcement, but the inclusion of health and safety as a core ESG pillar reflects sector norms. Regulatory expectations in pharmaceutical manufacturing are rigorous, and safety performance can affect site licensing and customer audits.
Energy management overlaps with climate action but also includes operational efficiency measures that reduce costs. For example, process optimization that lowers energy consumption delivers both environmental and financial benefits. Similarly, waste management in pharmaceutical manufacturing involves regulatory compliance, environmental impact, and cost control. Reducing waste can lower disposal costs and improve material utilization rates.
Diversity and inclusion, the fifth pillar, addresses workforce composition and workplace culture. While less directly connected to environmental performance, workforce policies can influence long-term resilience and regulatory compliance, particularly as ESG reporting standards expand to cover social metrics alongside environmental ones.
Notably, individual Axplora sites have received external recognition for sustainability performance. The company's Leverkusen site achieved EcoVadis Platinum status, and other European sites have earned strong ratings. EcoVadis assessments evaluate environmental management, labor practices, ethics, and sustainable procurement. Consequently, site-level recognition complements company-level commitments by demonstrating implementation at operational facilities.
Emissions reductions and renewable energy in practice
- Axplora's validated targets require a 42% reduction in Scope 1 and 2 emissions by 2030, covering direct emissions and purchased energy.
- The company has committed to a 25% reduction in Scope 3 emissions by 2030, which includes supply chain and downstream emissions.
- Renewable electricity reached 61% across all sites in 2024, with 100% renewable electricity at French manufacturing facilities.
- Absolute greenhouse gas emissions fell by 9% in 2023, while emissions intensity per million euros of sales dropped by 6%.
- Axplora uses Process Mass Intensity and a recycle, reuse, revalorize approach to improve manufacturing efficiency and reduce waste.
Supply chain implications for pharmaceutical buyers
Pharmaceutical companies evaluating suppliers now routinely request carbon data, emissions reduction plans, and evidence of progress. Axplora's SBTi validation provides a verifiable reference point for these assessments. For businesses managing Scope 3 emissions, supplier engagement is often the most challenging component of carbon accounting. Therefore, suppliers with validated targets can simplify the data collection process for their customers.
In addition, pharmaceutical supply chains face reputational and regulatory risks related to environmental performance. Product recalls, regulatory enforcement, and public scrutiny all carry commercial consequences. Consequently, buyers increasingly view supplier ESG performance as a risk management issue, not just a reporting requirement. Suppliers that can demonstrate progress on emissions, energy, and waste may gain a competitive advantage in customer audits and contract renewals.
However, businesses should distinguish between target-setting and delivery. Axplora's validated targets represent commitments, and the company has reported progress in recent years. Nevertheless, achieving long-term emissions reductions requires sustained investment, operational changes, and supplier collaboration. For procurement teams, this means tracking actual performance data over time and building relationships with suppliers who demonstrate consistent progress.
The pharmaceutical sector also faces specific challenges related to product integrity and regulatory compliance. Changes to manufacturing processes must not compromise product quality or violate regulatory standards. As a result, decarbonization in pharmaceutical manufacturing often proceeds more cautiously than in other industrial sectors. Buyers should expect gradual, evidence-based improvements rather than rapid transformations.
Moreover, the focus on Scope 3 emissions means that Axplora's own suppliers will need to reduce emissions for the company to meet its 25% target. This creates a ripple effect through the supply chain, potentially influencing raw material sourcing, logistics providers, and waste management contractors. Businesses further up the chain may therefore see increased requests for emissions data and reduction plans from their pharmaceutical manufacturing customers.
Additional information and authoritative sources
Businesses seeking further detail on science-based targets can consult the Science Based Targets initiative website, which provides guidance on target-setting and validation. The initiative publishes a database of companies with validated targets, allowing businesses to compare commitments across sectors.
For information on carbon reporting requirements in UK public procurement, the government's Procurement Policy Note 06/21 outlines expectations for suppliers bidding on contracts above certain thresholds. Although Axplora is not primarily a UK government supplier, the framework illustrates the direction of travel in public and private procurement.
Pharmaceutical companies can refer to guidance from the Medicines and Healthcare products Regulatory Agency for regulatory context on manufacturing standards. Environmental performance must align with existing pharmaceutical quality and safety requirements, which remain the primary regulatory focus.
Businesses interested in ESG compliance and carbon reporting services can explore structured support for meeting supplier expectations and regulatory requirements. Furthermore, companies preparing for PPN 06/21 or similar procurement frameworks may benefit from carbon reduction planning and reporting support to ensure submissions meet technical and commercial standards.